Table 1

Clinical Characteristics of AVERT Patients by Echocardiographic Study*

Echocardiographic Study (n = 575)No Echocardiographic Study (n = 166*)
Age (yrs)61 ± 1060 ± 13
Gender (% male)5866
NYHA functional class, I/II/III/IV (%)10/41/42/77/42/41/10
Systolic blood pressure (mm Hg)129 ± 20130 ± 23
Diastolic blood pressure (mm Hg)72 ± 1272 ± 13
Preoperative LVEF (%)58 ± 1456 ± 16
Past medical/surgical history (%)
 Neurologic events (stroke/RIND/TIA)56
 Diabetes mellitus1315
 Coronary artery disease3136
 Myocardial infarction713
 Congestive heart failure2126
 Carotid artery disease36
 Coronary artery bypass surgery47
 Heart valve surgery117
 Endocarditis (inactive or recent)88
Clinical events after valve implant (%)
 Thromboembolism (all reported)911
 Bleeding812
 Prosthetic valve endocarditis2.61.8
 All-cause death27

All numbers shown are mean ± SD, unless noted otherwise.

AVERT = Artificial Valve Endocarditis Reduction Trial; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; RIND = reversible ischemic neurologic deficit; TIA = transient ischemic attack.

  • * Excludes patients who died or had their prosthetic valves explanted before the start of the echocardiographic study.

  • p < 0.01.